OBJECTIVE: Experimental autoimmune myocarditis (EAM) is characterized by pronounced macrophage infiltration, cardiac necrosis, and cardiac fibrosis. Our previous studies have demonstrated that suppressed androgen receptor (AR) enables anti-inflammation to promote tissue repair by decreasing M1 macrophages and increasing M2 macrophages in an EAM model. Given that autophagy mediates inflammatory response in macrophages, we investigated whether AR inhibition executes its protective role in inflammation through the autophagy pathway in EAM. MATERIALS AND METHODS: To determine whether AR inhibition can perform its anti-inflammatory effects by upregulating autophagy, we pre-treated mice with 3-methyl adenine (3-MA), a pharmacological inhibitor of autophagy. Immunofluorescence assay and Western blot were used to detect autophagy levels and autophagy activity in five different groups. Immunofluorescence marked F4/80 and LC3 to illustrate the autophagy level in macrophages. TUNEL assays were used to detect the apoptosis level in heart tissue of five different groups. RESULTS: We demonstrated that AR inhibition resolves injury with sustained inhibition of inflammatory cytokines associated with enhanced autophagy, especially in macrophages. Increased LC3II/I expression corroborated complete autolysosome formation detected by electron microscopy and correlated with degradation of SQSTM1/p62 in the AR inhibition group by Western blot. These effects could be reversed within 3-MA, a pharmacological inhibitor of autophagy. Specifically, pharmacological inhibition of autophagy increased apoptosis and inflammation, which could be attenuated by AR inhibition. CONCLUSIONS: AR inhibition alleviates the inflammatory response and tissue apoptosis by enhancing autophagy, especially in macrophages.

OBJECTIVE:Alzheimer's disease (AD) has been considered as a metabolic disorder disease, which closely related to insulin signaling impairment. Therefore, identifying the potential mechanism of insulin resistance is important for AD treatment.MATERIALS AND METHODS:An APP/PS1 double transgenic AD mouse model was introduced to study insulin resistance in gut. The expressions of AD markers and key elements of insulin signaling were detected in ileum and intestinal macrophages of AD mice by immunohistochemistry. Furthermore, mouse intestinal macrophage cell line RAW264.7 was treated by Aβ25-35 or Aβ25-35 + insulin to explore the mechanism of insulin resistance in vitro. The expression of IR-β and the activation of cell signaling related proteins (Insulin receptor substrate 1 (IRS1), protein kinase B (AKT) and c-Jun N-terminal kinase (JNK)) in Aβ25-35-stimulated macrophages were performed via Western blotting.RESULTS:The expressions of IRS1, Aβ and Tuj in AD mice ileum were significantly different from WT mice (p<0.05). Also, there were significant discrepancies in the expressions of β2AR and eNOS in intestinal macrophages of two groups (p<0.05). After exposure to Aβ25-35, cell proliferation rate (p<0.01) of macrophage and the levels of TNF-α (p<0.01) and Il-6 (p<0.01) was significant elevated and treatment with insulin could reverse these changes (p<0.05). The amount of IR-β and the p-AKT/AKT ratio significantly decreased in Aβ25-35-treated macrophages (p<0.01), while the ratios of p-IRS1/IRS1 and p-JNK/JNK significantly enlarged (p<0.01). Furthermore, all the changes caused by Aβ25-35 treatment were attenuated by insulin addition.CONCLUSIONS:Activation of JNK pathway played an important role in insulin resistance of AD mice, suggesting that inhibition of JNK pathway might be a new strategy toward resolving insulin resistance related diseases, such as AD.